India's Glenmark Pharma up on positive early-stage results for blood cancer drug

Glenmark Pharmaceuticals

10/12/2024 05:05

** Shares of Glenmark Pharmaceuticals  GLEN.NS  rise 2.6% to
1,554 rupees
        ** GLEN top gainer on Nifty Pharma index  .NIPHARM ,
which is up 0.14%
  
    ** Ichnos Glenmark Innovation says early-stage results for
its blood cancer drug, ISB 2001, showed promising results 
    ** Ichnos Glenmark Innovation is a partnership between
Ichnos Sciences and Glenmark Pharma to develop cancer treatments
    ** ISB 2001 developed for treating advanced multiple
myeloma, a type of cancer developing in plasma cells 
    ** 83% of 18 patients in study showed partial or complete
response to treatment, with cancer going away completely in 20%
- co
    ** Stock set to snap a four-day losing streak
    ** Analysts' avg rating on GLEN at "buy; median PT is 1,700
rupees - LSEG data
    ** Stock up ~55% YTD, while pharma index is up 33%

 (Reporting by Yagnoseni Das in Bengaluru)
 ((Yagnoseni.Das@thomsonreuters.com;))